ZABOFLOXACIN D-ASPARTATE SESQUIHYDRATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C19H20FN5O4.2C4H7NO4.3H2O
Molecular Weight	1123.0344
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	2
Charge	0
Stereo Comments	Assumed Z-isomer

SHOW SMILES / InChI

Structure of ZABOFLOXACIN D-ASPARTATE SESQUIHYDRATE

Structure Search

SMILES

O.O.O.N[C@H](CC(O)=O)C(O)=O.N[C@H](CC(O)=O)C(O)=O.CO\N=C1/CN(CC12CNC2)C3=NC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O.CO\N=C6/CN(CC67CNC7)C8=NC9=C(C=C8F)C(=O)C(=CN9C%10CC%10)C(O)=O

InChI

InChIKey=CBRIHWAFFDZLQU-BOGMURSJSA-N

InChI=1S/2C19H20FN5O4.2C4H7NO4.3H2O/c2*1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17;2*5-2(4(8)9)1-3(6)7;;;/h2*4-5,10,21H,2-3,6-9H2,1H3,(H,27,28);2*2H,1,5H2,(H,6,7)(H,8,9);3*1H2/b2*23-14+;;;;;/t;;2*2-;;;/m..11.../s1

HIDE SMILES / InChI

Molecular Formula	C4H7NO4
Molecular Weight	133.1027
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H20FN5O4
Molecular Weight	401.3916
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT01658020 | https://clinicaltrials.gov/ct2/show/NCT01081964 | https://www.ncbi.nlm.nih.gov/pubmed/20403681

Zabofloxacin (also known as DW-224a), a fluoroquinolone antibiotic agent, is a dual inhibitor of both DNA gyrase and topoisomerase IV of Streptococcus pneumonia. Zabofloxacin successfully has completed phase III clinical trial in patients with acute bacterial exacerbation of the chronic obstructive pulmonary disease. In addition, in May 2012, IASO terminated phase II trial of oral zabofloxacin capsules in patients with moderate-to-severe community-acquired pneumonia due to financial considerations.

Originator

Approval Year

PubMed

Title	Date	PubMed
New treatment options for lower respiratory tract infections.	2017-09	28762839
DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.	2010-07	20403681
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.	2008-09	18620833
Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent.	2004-11	15573468

Patents

Sample Use Guides

In Vivo Use Guide

Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:25:44 GMT 2025` Edited by `admin` on `Tue Apr 01 21:25:44 GMT 2025`
Record UNII	5ES4SV75WA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

D-ASPARTIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-((8Z)-8-(METHOXYIMINO)-2,6-DIAZASPIRO(3.4)OCT-6-YL)-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, HYDRATE (2:2:3)

Preferred Name

English

ZABOFLOXACIN D-ASPARTATE SESQUIHYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

5ES4SV75WA